SVRA
Savara Inc.NASDAQHealthcare$5.56-0.36%ClosedMarket Cap: $1.14B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.09
P/S
0.00
EV/EBITDA
-9.31
DCF Value
$-0.00
FCF Yield
-8.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-84.0%
ROA
-49.1%
ROIC
-53.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-32.2M | $-0.13 |
| FY 2025 | $0.00 | $-118.8M | $-0.53 |
| Q3 2025 | $0.00 | $-29.6M | $-0.14 |
| Q2 2025 | $0.00 | $-30.4M | $-0.14 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2025-12-23Wells FargoOverweight
2025-12-18OppenheimerOutperform
2025-11-14CitizensMarket Outperform
2025-11-13JMP SecuritiesMarket Outperform
2025-10-23Trading Activity
Insider Trades
View AllLowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.31
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.